These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11875815)

  • 1. [A case of polymyositis complicated with pulmonary tuberculosis concerned with steroid resistance due to rifampin administration].
    Shinoda C; Hayashi R; Kawasaki A; Maruyama M; Kobayashi M
    Nihon Kokyuki Gakkai Zasshi; 2001 Dec; 39(12):955-60. PubMed ID: 11875815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of pulmonary tuberculosis with acute renal failure caused by readministration of rifampicin].
    Kuroda F; Yagi T; Yamagishi F; Mizutani F; Sasaki Y; Wada A
    Kekkaku; 1999 Nov; 74(11):803-7. PubMed ID: 10599213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-course chemotherapy of tuberculosis with pyrazinamide].
    Asai S; Futsuki Y; Tomari S; Araki J
    Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study on the cases in which INH or RFP was discontinued during treatment for pulmonary tuberculosis].
    Harada S; Takamoto M; Ishibashi T; Mohri M; Sato K; Yamagishi F; Sasaki Y; Tanabe K; Sato R; Fujino T; Tano M; Tanizawa M; Sakatani M; Morimoto T; Kawahara S; Hotta N; Shigeto E; Nishimura K; Abe T; Iwanaga T; Oe T; Shimazu K; Ebihara M; Nakagawa S; Kuba M;
    Kekkaku; 2001 May; 76(5):427-36. PubMed ID: 11449698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of successful desensitization therapy for isoniazid-induced pneumonitis].
    Nishizawa Y; Yasui M; Yamamori C; Tagami A; Fujimura M; Nakao S
    Nihon Kokyuki Gakkai Zasshi; 2004 Jul; 42(7):649-54. PubMed ID: 15357268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intensive chemotherapy of pulmonary tuberculosis].
    Shesterina MV; Gavrilenko VS; Tarasova EF; Sokolova GV; Tregubov IuG
    Probl Tuberk; 1980 Jul; (7):20-22. PubMed ID: 6997865
    [No Abstract]   [Full Text] [Related]  

  • 8. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of multidrug resistance during treatment of isoniazid-resistant tuberculosis.
    Koh WJ; Kwon OJ; Park YK; Lew WJ; Bai GH
    Eur Respir J; 2005 Sep; 26(3):557. PubMed ID: 16135740
    [No Abstract]   [Full Text] [Related]  

  • 10. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the streptomycin twice weekly with INH and RFP for initial therapy of pulmonary tuberculosis].
    Toyota E; Suzuki T; Tagawa K; Takahara M; Ito M; Arai T; Kabe J; Baba H
    Kekkaku; 1994 Sep; 69(9):559-63. PubMed ID: 7967317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR; Agarwal SK; Shah KV
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifapentine for the treatment of tuberculosis: is it all it can be?
    Gordin FM
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
    [No Abstract]   [Full Text] [Related]  

  • 14. [Short-course chemotherapy for pulmonary tuberculosis. 1. Clinical effect of RFP, INH and EB regimen for 9 months in the original treatment for pulmonary tuberculosis (author's transl)].
    Oda T
    Kekkaku; 1980 Jul; 55(7):331-9. PubMed ID: 7206413
    [No Abstract]   [Full Text] [Related]  

  • 15. [A study on the intensive chemotherapy for previously untreated pulmonary tuberculosis--comparison of two regimens, SM-INH-RFP and SM-INH-EB (author's transl)].
    Maekawa N; Kuze F; Inaba N; Ohi Y; Yamada E; Yasubuchi Y
    Kekkaku; 1977 Jun; 52(6):299-306. PubMed ID: 904139
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
    Kononets AS
    Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Case of pulmonary tuberculosis in late stage of pregnancy].
    Nakanishi N; Moritaka T; Ueda N
    Kekkaku; 2004 Oct; 79(10):569-71. PubMed ID: 15631108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of drug-resistant pulmonary tuberculosis treated successfully following disappearance of rifampicin resistance after 17 years' chemotherapy].
    Shigeto E; Murakami I; Yokosaki Y
    Kekkaku; 2001 Apr; 76(4):379-83. PubMed ID: 11398329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
    Martínez E; Collazos J; Mayo J
    Clin Infect Dis; 1998 Nov; 27(5):1329-30. PubMed ID: 9827298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.